126 related articles for article (PubMed ID: 25675439)
21. Synthesis and anticancer evaluation of 6-azacyclonol-2,4,6-trimethylpyridin-3-ol derivatives: M3 muscarinic acetylcholine receptor-mediated anticancer activity of a cyclohexyl derivative in androgen-refractory prostate cancer.
Karmacharya U; Chaudhary P; Lim D; Dahal S; Awasthi BP; Park HD; Kim JA; Jeong BS
Bioorg Chem; 2021 May; 110():104805. PubMed ID: 33725508
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma.
De Monte C; Carradori S; Secci D; D'Ascenzio M; Guglielmi P; Mollica A; Morrone S; Scarpa S; Aglianò AM; Giantulli S; Silvestri I
Eur J Med Chem; 2015 Nov; 105():245-62. PubMed ID: 26498571
[TBL] [Abstract][Full Text] [Related]
23. 3-O-Alkyl-2,3-dehydrosilibinins: Two synthetic approaches and in vitro effects toward prostate cancer cells.
Zhang S; Vue B; Huang M; Zhang X; Lee T; Chen G; Zhang Q; Zheng S; Wang G; Chen QH
Bioorg Med Chem Lett; 2016 Jul; 26(14):3226-3231. PubMed ID: 27261177
[TBL] [Abstract][Full Text] [Related]
24. In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
Cruz EC; Carecho AR; Saidel ME; Montanari CA; Leitão A
Bioorg Med Chem Lett; 2017 Feb; 27(3):546-550. PubMed ID: 28011219
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of quinoline derivatives as potential anti-prostate cancer agents and Pim-1 kinase inhibitors.
Li K; Li Y; Zhou D; Fan Y; Guo H; Ma T; Wen J; Liu D; Zhao L
Bioorg Med Chem; 2016 Apr; 24(8):1889-97. PubMed ID: 26979485
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
Lao K; Sun J; Wang C; Wang Y; You Q; Xiao H; Xiang H
Bioorg Med Chem Lett; 2017 Sep; 27(17):4212-4217. PubMed ID: 28757062
[TBL] [Abstract][Full Text] [Related]
27. 3-
Wu S; Chen G; Zhang Q; Wang G; Chen QH
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770829
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
Jorda R; Řezníčková E; Kiełczewska U; Maj J; Morzycki JW; Siergiejczyk L; Bazgier V; Berka K; Rárová L; Wojtkielewicz A
Eur J Med Chem; 2019 Oct; 179():483-492. PubMed ID: 31271960
[TBL] [Abstract][Full Text] [Related]
29. Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
Ferla S; Bassetto M; Pertusati F; Kandil S; Westwell AD; Brancale A; McGuigan C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3636-40. PubMed ID: 27301368
[TBL] [Abstract][Full Text] [Related]
30. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
31. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
32. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
Wang J; Lu Z; Wu C; Li Y; Kong Y; Zhou R; Shi K; Guo J; Li N; Liu J; Song W; Wang H; Zhu M; Xu H
Prostate; 2019 Jan; 79(1):62-72. PubMed ID: 30242862
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
Chen H; Yu YZ; Tian XM; Wang CL; Qian YN; Deng ZA; Zhang JX; Lv DJ; Zhang HB; Shen JL; Yuan M; Zhao SC
Bioorg Med Chem; 2019 Jan; 27(1):133-143. PubMed ID: 30482547
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, biological evaluation and molecular docking study of 1-amino-2-aroylnaphthalenes against prostate cancer.
Rai R; Dutta RK; Singh S; Yadav DK; Kumari S; Singh H; Gupta RD; Pratap R
Bioorg Med Chem Lett; 2018 May; 28(9):1574-1580. PubMed ID: 29606573
[TBL] [Abstract][Full Text] [Related]
36. Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.
Ryu BJ; Kim N; Kim JT; Koo TS; Yoo SE; Jeong SH; Kim SH; Kang NS
Bioorg Med Chem Lett; 2013 Jul; 23(13):3887-90. PubMed ID: 23727044
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and biological evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines.
Chen H; Xu F; Liang X; Xu BB; Yang ZL; He XL; Huang BY; Yuan M
Bioorg Med Chem Lett; 2015 Jan; 25(2):285-7. PubMed ID: 25488843
[TBL] [Abstract][Full Text] [Related]
38. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
39. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, pharmacological evaluation and docking studies of progesterone and testosterone derivatives as anticancer agents.
Jabeen M; Choudhry MI; Miana GA; Rahman KM; Rashid U; Khan HU; Arshia ; Sadiq A
Steroids; 2018 Aug; 136():22-31. PubMed ID: 29772243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
